Category Archives: Infringement

DC grant of PI vacated and remanded as Lite-Netics’ infringement allegations not objectively baseless (First Amendment issues relating to customer letters addressed)

Posted on February 23, 2023 by Patrick J. Halloran, Ph.D., J.D.

Lite-Netics, LLC v. Nu Tsai Capital LLC, Holiday Bright Lights (“HBL”) Docket No. 2023-1146 (h https://cafc.uscourts.gov/opinions-orders/23-1146.OPINION.2-17-2023_2082508.pdf) LOURIE, TARANTO, STARK February 17, 2023 Brief Summary:   DC grant of PI vacated and remanded based on the DC’s abuse of discretion in … Continue reading →

Posted in Claim Construction, Doctrine of equivalents, Infringement, Injunction, Prosecution History Estoppel | Leave a comment

FC panel affirms DC obviousness and non-infringement findings regarding Genentech’s Esbriet® patents

Posted on January 13, 2023 by Patrick J. Halloran, Ph.D., J.D.

Genentech, Inc., Intermune, Inc. v. Sandoz Inc., LEK Pharmaceuticals, D.D. Docket No. 2022-1595 (https://cafc.uscourts.gov/opinions-orders/22-1595.OPINION.12-22-2022_2052253.pdf) NEWMAN, LOURIE, PROST December 22, 2022 Brief Summary:   DC findings that Genetech’s disputed Esbriet® patents are invalid for obviousness and not infringed by Sandoz’s ANDA … Continue reading →

Posted in Generics / ANDA, Infringement, Method claims, Obviousness, Obviousness (Secondary Considerations) | Leave a comment

DC decision of infringement and no invalidity of Pharmacyclic’s BTK inhibitor-related patents affirmed

Posted on November 29, 2022 by Patrick J. Halloran, Ph.D., J.D.

Pharmacyclics LLC, Jannsen Biotech, Inc. v. Alvogen, Inc., Natco Pharma Limited Docket No. 2021-2270 (https://cafc.uscourts.gov/opinions-orders/21-2270.OPINION.11-15-2022_2033497.pdf) (Non-Precedential) CHEN, BRYSON, HUGHES November 15, 2022 Brief Summary:   DC decisions that Pharmacyclic’s patents were infringed and not invalid for lack of written description, … Continue reading →

Posted in Anticipation (35 USC 102), Double Patenting, Enablement, Generics / ANDA, Incorporation by Reference, Infringement, Method claims, Obviousness, Obviousness (Secondary Considerations), Priority, Public Accessibility, Written description | Leave a comment

DC decision of no infringement by Eagle’s ANDA specification and denial of DJ affirmed

Posted on August 19, 2022 by Patrick J. Halloran, Ph.D., J.D.

Par Pharmaceutical, Inc. et al. v. Eagle Pharmceuticals, Inc. Docket No. 2021-2342 (https://cafc.uscourts.gov/opinions-orders/21-2342.OPINION.8-18-2022_1993064.pdf) MOORE, PROST, HUGHES August 18, 2022 Brief Summary:   DC finding of no infringement under 271(e)(2) affirmed based on Eagle’s ANDA specification to which Eagle is bound, … Continue reading →

Posted in Claim Construction, Generics / ANDA, Infringement, Method claims, Safe Harbor, FDA exemptions (271(e)(1)) | Leave a comment

DC denial of Thales’ motion to enjoin Philips’ ITC exclusion order as Thales did not show it was likely to suffer irreparable harm affirmed

Posted on July 27, 2022 by Patrick J. Halloran, Ph.D., J.D.

Koninklijke Philips N.V. et al. v. Thales DIS AIS USA LLC, et al. Docket No. 2021-2106 (https://cafc.uscourts.gov/opinions-orders/21-2106.OPINION.7-13-2022_1977322.pdf) MOORE, DYK, CHEN July 13, 2022 Brief Summary:   DC denial of Thales motion to enjoin Philips from seeking ITC exclusion order affirmed … Continue reading →

Posted in Infringement, International Trade Commission, Software | Leave a comment

DC indefiniteness conclusion vacated for incorrect claim construction, grant of SJ regarding jurisdiction vacated

Posted on June 28, 2022 by Patrick J. Halloran, Ph.D., J.D.

Univ. of Massachusetts, Carmel Labs., LLC v. L’Oreal S.A. and L’Oreal USA, Inc. Docket No. 2020-1969 (https://cafc.uscourts.gov/opinions-orders/21-1969.OPINION.6-13-2022_1964183.pdf) PROST, MAYER, TARANTO June 13, 2022 Brief Summary:   DC indefiniteness finding vacated due to improper claim construction and grant of SJ for … Continue reading →

Posted in Claim Construction, Claim Differentiation, Infringement, Inter Parties Review (IPR), IPR, Prosecution History Estoppel, Wherein, Written description | Leave a comment

DC denial of on-sale bar defense reversed; claim construction affirmed; grant of enhanced damages reversed based on attorney opinion; reasonably royalty affirmed

Posted on May 12, 2022 by Patrick J. Halloran, Ph.D., J.D.

Sunoco Partners Marketing & Terminals, L.P. v. U.S. Venture, Inc. et al. (“Venture”) Docket No. 2020-1640, -1641 (https://cafc.uscourts.gov/opinions-orders/20-1640.OPINION.4-29-2022_1943607.pdf) PROST, REYNA, STOLL April 29, 2022 Brief Summary:  DC denial of on-sale bar defense reversed; claim construction affirmed; grant of enhanced damages … Continue reading →

Posted in Claim Construction, Claim Differentiation, Damages, Experimental Use, Expert Testimony, Infringement, Lost Profits, On-Sale Bar, Royalties, Willfullness | Leave a comment

DC grant of SJ reversed and remanded due to improper finding of indefiniteness

Posted on April 21, 2022 by Patrick J. Halloran, Ph.D., J.D.

Niazi Licensing Corporation v. St. Jude Medical S.C., Inc. Docket No. 2021-1864 (https://cafc.uscourts.gov/opinions-orders/21-1864.OPINION.4-11-2022_1934126.pdf) TARANTO, BRYSON, STOLL April 11, 2022 Brief Summary:   DC findings of indefiniteness reversed, but induced infringement, exclusion of expert witness report and damages findings affirmed. Summary:  … Continue reading →

Posted in Claim Construction, Claim Differentiation, Damages, Expert Testimony, Indefiniteness, Inducement to Infringe, Infringement, Medical Devices, Method claims, Prosecution History Estoppel, Royalties, Written description | Leave a comment

DC decisions of induced infringement of patent asserted by Meso and non-infringement of non-asserted patents as requested by Roche vacated and remanded

Posted on April 15, 2022 by Patrick J. Halloran, Ph.D., J.D.

Roche Diagnostics Corp., Bioveris Corp. v. Meso Scale Diagnostics, LLC Docket No. 2021-1609, -1633 (https://cafc.uscourts.gov/opinions-orders/21-1609.OPINION.4-8-2022_1933410.pdf) NEWMAN (D), PROST, TARANTO April 8, 2022 Brief Summary:   DC findings of induced infringement of patents asserted by Meso and non-infringement of non-asserted patents … Continue reading →

Posted in Assignment / Ownership, Damages, Inducement to Infringe, Infringement, Licensing | Leave a comment

DC reversed on WD of genus claims and patent co-ownership, affirmed on no willfulness and remanded for damages calculation

Posted on March 28, 2022 by Patrick J. Halloran, Ph.D., J.D.

BASF Plant Science, L.P., Cargill, Inc. v. Commonwealth Scientific, et al. (“CSIRO”) Docket No. 2020-1415-16, 2020-1919-20 (https://cafc.uscourts.gov/opinions-orders/20-1415.OPINION.3-15-2022_1921729.pdf) NEWMNA (D), TARANTO, CHEN March 15, 2022 Brief Summary:   Following a dispute regarding a collaboration agreement, FC panel affirmed DC fining on … Continue reading →

Posted in Assignment / Ownership, Infringement, Inventorship, Licensing, Royalties, Venue, Willfullness, Written description | Leave a comment